Email this article Specific features of Brodie’s tumors
- Authors: Denchik D.A.1, Vorotnikov I.K.1, Lyubchenko L.N.1, Anurova O.A.1, Bykova A.V.1
-
Affiliations:
- Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 3 (2010)
- Pages: 21-23
- Section: MAMMOLOGY. LECTURE
- Published: 28.08.2010
- URL: https://ojrs.abvpress.ru/ojrs/article/view/245
- DOI: https://doi.org/10.17650/1994-4098-2010-0-3-21-23
- ID: 245
Cite item
Full Text
Abstract
Brodie’s tumors are comparatively rare in oncological care and difficult-to-diagnose masses with an unpredictable course, predilection for recurrences, and a high probability of malignization. These tumors have a two-component structure with the predominant develop- ment of a connective tissue component that is absolute in sarcomas and, in a group of fibroepithelial tumors, combines with the parallel development of epithelial tissue.
The etiology of Brodie’s tumor is unclear, so is its pathogenesis. Molecular genetic studies have shown that the carriers of germ line missence-mutation R1699W in the BRCA1 gene have an increased risk of developing malignant Brodie’s tumor, but allele losses at the D22S264 locus of the TP5 gene determine the progression of the disease. Deletion of the short-arm of chromosome 1 (1p) and allelic imbalance are associated with the more aggressive course and recurrences of Brodie’s tumor.
A complex clinicomorphological and molecular genetic study will help answer some questions concerning the diagnosis and treatment of Brodie’s tumors.
About the authors
D. A. Denchik
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
I. K. Vorotnikov
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
L. N. Lyubchenko
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: clingen@mail.ru
Russian Federation
O. A. Anurova
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
A. V. Bykova
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
References
Supplementary files
